Fourth Annual Chicago Supportive Oncology Conference

Community Oncology

Volume 2, Number 5 (September/October 2005)

Letter from the Editor

375

 

Doing well by doing good

Lee S. Schwartzberg, MD, FACP, Editor-in-Chief

The West Clinic, Memphis, TN

Herceptin has a second act in breast cancer, but will it be too costly to deliver? An important question on quality care, addressed by several articles in this issue.

full text 51 kb

Community Dialogue

379

 

Your open line to the CMS

Community Oncology interviews Peter B. Bach, MD, MAPP, Senior Adviser to the Administrator, Centers for Medicare & Medicaid Services

With a strong reputation for research on quality cancer care, Dr. Bach was a choice many community oncologists approved of when he was selected as a special cancer policy adviser. We spoke with him recently about what lies ahead when it comes to the demonstration project, pay for performance, reimbursements, and more.

full text 107 kb

Community Translations

388

 

Trastuzumab in adjuvant therapy for early-stage breast cancer

Summary by Matt Stenger, MS; reviewed by Edith A. Perez, MD, Mayo Clinic, Jacksonville, FL

It was the topic that set ASCO on its ear: current trials now indicate that adding trastuzumab prolongs disease-free survival. The data are so strong, they warrant a change in the standard of care from adjuvant anthracycline therapy, with or without taxanes, to adjuvant treatment with trastuzumab for eligible patients with HER2+ resected breast cancer.

full text 115 kb

Review Articles

397

 

The adverse health effects of occupational exposure to hazardous drugs

Susan Martin, RN, DNSc, AOCN®

Long Beach, NY

Concern has been growing about the safety of healthcare workers who handle chemotherapy drugs. Acute symptoms in nursing staff include nausea, vomiting, headaches, dizziness, hair loss, and liver damage. Also worrisome: risks to reproductive health, fetal abnormalities, and risk for leukemia.

abstract full text 101 kb

403

 

Developing a hazardous drug safe-handling program

Martha Polovich, MN, RN, AOCN®

Southern Regional Health System, Riverdale, GA

The government has issued warnings and alerts for the past 20 years to protect healthcare workers. Implementing a comprehensive safety program poses a number of challenges, not least of which is adherence. The author offers a step-by-step approach.

abstract full text 93 kb

Original Research

418

 

Importance of molecular confirmation in the diagnosis of myeloproliferative disorders

Dennis Slater, MD, Karyn Ronski, BS, Judy Delach, MS, Peter Benn, PhD, and Min Fang, MD, PhD

William W. Backus Hospital, Norwich, CT, and University of Connecticut Health Center, Farmington, CT

The authors report a Philadelphia chromosome–positive case with pathological features of a myeloproliferative disorder consistent with chronic myeloid leukemia. But things weren’t as they seemed.

abstract full text 127 kb

Challenging Cases/Rare Cancers

429

 

Lymphoma with effusion in an HIV patient

Simone Van-Horne, MD, Pauline Germaine, DO, Nancy Zieber, RN, and David H. Henry, MD

Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA

A 42-year-old man with a history of HIV and Kaposi’s sarcoma complained of increasing shortness of breath, weakness, and abdominal pain. How he was treated.

abstract full text 160 kb

Economics/Practice Management

435

 

Spotting the time bombs in your managed care contracts

Frank Fedor, JD

Murphy Austin Adams Schoenfeld LLP, Sacramento, CA

The author describes 10 areas where things can go badly and how you can avoid the traps.

abstract full text 100 kb

Quality Care

441

 

Better margins, better quality: seizing the moment

Alice G. Gosfield, JD

Alice G. Gosfield and Associates PC, Philadelphia, PA

The author advocates five principles that would improve care, save time, and increase financial margins.

abstract full text 105 kb

Psychosocial Oncology

446

 

Patients’ and families’ receptivity to discussions about future healthcare

Lisa Stearns, MD, Sarah Butler, and Joelle Hollander, MSPH

Valley Cancer Pain Treatment Center, Scottsdale, AZ

A small study shows that with guidance and encouragement from physicians and their staff, patients and their loved ones are more likely to prepare an advance directive.

abstract full text 116 kb

Book Review

408

 

The high cost of low-priced cancer drugs

Dangerous Doses: How Counterfeiters Are Contaminating America’s Drug Supply, by Katherine Eban, Harcourt Press

Reviewed by Dawn Holcombe, FACMPE, Oncology Network of Connecticut, South Windsor, CT

Dangerous Doses chronicles the investigations launched over the past 4 years in Florida to prosecute wholesalers and profiteers intent on selling bad drugs to doctors and patients.

full text 45 kb

Community Alert

410

 

Finding programs to help patients pay for drugs is now much easier

Cori Vanchieri

Several hundred drug assistance programs stand ready to offer free or low-cost drugs to patients in need. A new Web site and toll-free number help navigate the system.

full text 41 kb

Technology

425

 

Results of our EMR survey: what readers told us

Edwin S. Geffner

Readers share their experiences using electronic medical record (EMR) systems.

full text 52 kb

Washington Update

453

 

Through shared data, a new NCI program aims to speed delivery of innovative care

Cori Vanchieri

Politicians from both sides of the aisle are coming together on this issue.

full text 51 kb

454

 

Consequences of the Medicare Modernization Act

Ted Okon and Steve Coplon

Community Oncology Alliance, Memphis, TN

Seven reasons why the Competitive Acquisition Program is the wrong solution.

full text 56 kb

© 2005 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.